My HPRA: Register

SGLT2 inhibitors - Important Safety Information from Janssen-Cilag Limited, AstraZeneca Limited and Boehringer Ingelheim Limited as approved by the HPRA

Notice type: 3rd Party Publications

Date: 21/03/2016

  

Problem Or Issue:
Important Safety Information communication from Janssen-Cilag Limited, AstraZeneca Limited and Boehringer Ingelheim Limited on updated advice on the risk of diabetic ketoacidosis during treatment with SGLT2 inhibitors - Invokana (canagliflozin), Vokanamet (canagliflozin/metformin), Forxiga (dapagliflozin), Xigduo (dapagliflozin/metformin), Jardiance (empagliflozin), Synjardy (empagliflozin/metformin)

« Back